Trade OTLK anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Outlook Therapeutics, Inc. (OTLK) is trading at US$0.67, up 2.70% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$157.06M. Over the past 52 weeks, OTLK has traded between US$0.16 and US$2.54. On Syfe you can trade OTLK with $0 commission and add it to your watchlist.
| Previous close | US$0.65 |
|---|---|
| Market cap | US$157.06M |
| 52-week range | US$0.16 – US$2.54 |
| Volume | 6.35M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Year: 2016
Outlook Therapeutics Says Lytenava Gets FDA Approval for Retinal Disease Treatment
Jul 24, 7:18 PM · MT Newswires
Outlook Therapeutics, Inc. (OTLK) stock is trading at US$0.67, +2.70% from the previous close of US$0.65.
The market cap for Outlook Therapeutics, Inc. (OTLK) stock is approximately US$157.06M.
The 52-week high for Outlook Therapeutics, Inc. (OTLK) stock is US$2.54.
The 52-week low for Outlook Therapeutics, Inc. (OTLK) stock is US$0.16.
Outlook Therapeutics, Inc. (OTLK) does not currently pay a dividend.
Stay on top of OTLK
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
